Evidence map›Paper›PMID 38014132›Full record

ArticlemedRxiv : the preprint server for health sciences2023

Clinical practice recommendations on lipoprotein apheresis for children with homozygous familial hypercholesterolemia: an expert consensus statement from ERKNet and ESPN.

M Doortje Reijman, D Meeike Kusters, Jaap W Groothoff, Klaus Arbeiter, Eldad J Dann, Lotte M de Boer, Sarah D de Ferranti, Antonio Gallo, Susanne Greber-Platzer, Jacob Hartz and 11 more

Open access · greenAbstract readPreprint
PubMed Full text at PMC Publisher
In one paragraph

Article in medRxiv : the preprint server for health sciences, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 1 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

21 authors at 14 institutions in 11 countries.

M Doortje ReijmanAmsterdam UMC, University of Amsterdam, Department of Paediatrics, Amsterdam Cardiovascular Sciences, Amsterdam Gastroenterology Endocrinology Metabolism, Meibergdreef 9, Amsterdam, Netherlands.ORCID 0000-0003-0971-1936
D Meeike KustersAmsterdam UMC, University of Amsterdam, Department of Paediatrics, Amsterdam Cardiovascular Sciences, Amsterdam Gastroenterology Endocrinology Metabolism, Meibergdreef 9, Amsterdam, Netherlands.
Jaap W GroothoffAmsterdam UMC, University of Amsterdam, Department of Paediatrics, Amsterdam Cardiovascular Sciences, Amsterdam Gastroenterology Endocrinology Metabolism, Meibergdreef 9, Amsterdam, Netherlands.
Klaus ArbeiterDivision of Paediatric Nephrology and Gastroenterology, Department of Paediatrics and Adolescent Medicine, Medical University of Vienna, Vienna, Austria.
Eldad J DannBlood Bank and apheresis unit Rambam Health care campus, Haifa, Israel.
Lotte M de BoerAmsterdam UMC, University of Amsterdam, Department of Paediatrics, Amsterdam Cardiovascular Sciences, Amsterdam Gastroenterology Endocrinology Metabolism, Meibergdreef 9, Amsterdam, Netherlands.ORCID 0000-0002-1208-354X
Sarah D de FerrantiDepartment of Cardiology, Boston Children's Hospital, Boston, MA, USA, Department of Pediatrics, Harvard Medical School, Boston, MA, USA.ORCID 0000-0002-8561-6781
Antonio GalloSorbonne Université, INSERM, UMR 1166, Lipidology and cardiovascular prevention Unit, Department of Nutrition, APHP, Hôpital Pitié-Salpêtrière F-75013 Paris, France.ORCID 0000-0002-8887-994X
Susanne Greber-PlatzerClinical Division of Paediatric Pulmonology, Allergology and Endocrinology, Department of Paediatrics and Adolescent Medicine, Medical University Vienna, Vienna, Austria.ORCID 0000-0002-3706-8370
Jacob HartzDepartment of Cardiology, Boston Children's Hospital, Boston, MA, USA, Department of Pediatrics, Harvard Medical School, Boston, MA, USA.
Lisa C HudginsThe Rogosin Institute, Weill Cornell Medical College, New York, New York, USA.
Daiana IbarretxeVascular Medicine and Metabolism Unit (UVASMET), Hospital Universitari Sant Joan; Universitat Rovira i Virgili; Institut Investigació Sanitària Pere Virgili (IISPV)-CERCA, Spain; Centro de Investigación Biomédica en Red en Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, Spain.
Meral KayikciogluDepartment of Cardiology, Medical Faculty, Ege University, 35100 Izmir, Turkey.ORCID 0000-0003-3692-5227
Reinhard KlingelApheresis Research Institute, Stadtwaldguertel 77, 50935 Cologne, Germany (www.apheresis-research.org).
Genovefa D KolovouMetropolitan Hospital, Department of Preventive Cardiology. 9, Ethn. Makariou & 1, El. Venizelou, N. Faliro, 185 47, Athens, Greece.
Jun OhUniversity Medical Center Hamburg/Eppendorf, Martinistrasse 52, 20246 Hamburg, Germany.
R Nils PlankenDepartment of Radiology and nuclear medicine, Amsterdam UMC, location AMC, Meibergdreef 9, 1105 AZ Amsterdam, Netherlands.ORCID 0000-0003-3940-4670
Claudia StefanuttiDepartment of Molecular Medicine, Lipid Clinic and Atherosclerosis Prevention Centre, 'Umberto I' Hospital 'Sapienza' University of Rome, I-00161 Rome, Italy.
Christina TaylanPaediatric Nephrology, Children's and Adolescents' Hospital, University Hospital of Cologne, Faculty of Medicine, University of Cologne, Kerpener Str. 62, 50937, Cologne, Germany.
Albert WiegmanAmsterdam UMC, University of Amsterdam, Department of Paediatrics, Amsterdam Cardiovascular Sciences, Amsterdam Gastroenterology Endocrinology Metabolism, Meibergdreef 9, Amsterdam, Netherlands.ORCID 0000-0001-6223-5671
Claus Peter SchmittPediatric Nephrology, Center for Pediatric and Adolescent Medicine, University of Heidelberg, Germany.ORCID 0000-0003-4487-3332
Amsterdam University Medical Centers · NLBoston Children's Hospital · USMedical University of Vienna · ATCornell University · USEge University · TRGenesis Research Institute · JPHeidelberg University · DEInserm · FRInstituto de Salud Carlos III · ESMetropolitan Hospital · GRPoliclinico Umberto I · ITRambam Health Care Campus · ILUniversität Hamburg · DEUniversity of Cologne · DE

Funding

The Use of Mobile Health Technology and Behavioral Economics to Encourage Adherence to Statins in Adolescents with Familial HypercholesterolemiaK23HL145109 · NHLBI · BOSTON CHILDREN'S HOSPITAL · PI HARTZ, JACOB · 2019 to 2023
$849k
NHLBI NIH HHS K23 HL145109
6 · The paper itself

Abstract

Homozygous familial hypercholesterolaemia is a life-threatening genetic condition, which causes extremely elevated LDL-C levels and atherosclerotic cardiovascular disease very early in life. It is vital to start effective lipid-lowering treatment from diagnosis onwards. Even with dietary and current multimodal pharmaceutical lipid-lowering therapies, LDL-C treatment goals cannot be achieved in many children. Lipoprotein apheresis is an extracorporeal lipid-lowering treatment, which is well established since three decades, lowering serum LDL-C levels by more than 70% per session. Data on the use of lipoprotein apheresis in children with homozygous familial hypercholesterolaemia mainly consists of case-reports and case-series, precluding strong evidence-based guidelines. We present a consensus statement on lipoprotein apheresis in children based on the current available evidence and opinions from experts in lipoprotein apheresis from over the world. It comprises practical statements regarding the indication, methods, treatment targets and follow-up of lipoprotein apheresis in children with homozygous familial hypercholesterolaemia and on the role of lipoprotein(a) and liver transplantation.

Indexed as

cholesterolconsensus statementhomozygous familial hypercholesterolemiaLDLlipoprotein apheresispaediatrics

Identifiers

PMID38014132
PMCPMC10680892
OpenAlexW4388693102

What Socratic holds

Textmetadata
LicenceCC BY-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.